A Strongly recommended because there is strong scientific evidence. B Recommended because there is scientific evidence. C1 Recommended although there is no scientific evidence. C2 Not recommended because there is no scientific evidence. D Not recommended because there is evidence showing that it is ineffective or harmful.
This article presents a synopsis of the guidelines in English.
Diagnosis

CQ1-1 What are risk factors for pancreatic cancer?
The below-mentioned risk factors have been reported to have evidences supporting the relationship between the factors and pancreatic cancer: There is no scientific evidence of effective second-line chemotherapy within the insurance allowance in this country, but some reports suggest effectiveness. Some recent randomized clinical trials in other countries have reported effective second-line chemotherapy. Second-line chemotherapy can be considered in patients whose physical status is good and are fully informed after a detailed explanation (Grade C1).
Radiotherapy
CQ3-1 Is chemoradiation effective for locally advanced unresectable pancreatic cancer? RECOMMENDATION 3-1
Chemoradiation is effective for locally advanced unresectable pancreatic cancer and is recommended as one of the options for treatment (Grade B).
CQ3-2 What is the standard combined chemotherapy for chemoradiation for locally advanced unresectable pancreatic cancer? RECOMMENDATION 3-2 5-fluorouracil (5-FU) (Grade B) is the standard chemotherapy for chemoradiation for locally advanced pancreatic cancer.
Although there is no definite evidence supporting GEM-based chemoradiation, some report its usefulness. A safe regimen of GEM-based chemoradiation can be considered as one of the options for treatment after the procedure is fully explained and the patient provides informed consent (Grade C1).
CQ3-3 Is the lymph node included in the clinical standard field of external radiation therapy for locally advanced unresectable pancreatic cancer? RECOMMENDATION 3-3
There have been no prospective randomized clinical trials concerning this CQ. Radiation including the tumor and the positive lymph nodes in the radiation field is recommended prophylactically, although there is no supportive scientific evidence (Grade C1).
CQ3-4 Is intraoperative radiation effective for locally advanced pancreatic cancer?
There are reports of the efficacy of intraoperative radiation for locally advanced unresectable pancreatic cancer. However, there is no scientific evidence that intraoperative radiation improves the clinical course of locally advanced unresectable pancreatic cancer (Grade C1).
CQ3-5 Does chemoradiation improve the quality of life of patients with unresectable pancreatic cancer? 
EBM-based clinical guidelines for pancreatic cancer
Preservation of the stomach decreases the operation time and blood loss in pancreatoduodenectomy but does not decrease the survival rate after a surgical resection (Grade C1).
CQ4-3 Does combined portal vein resection improve the clinical outcome of patients with pancreatic head cancer?
The effect of prophylactic portal vein resection intended to increase the curability on the clinical course of patients with pancreatic cancer is unclear. A portal vein resection is indicated when surgical and dissection margins can be free from cancer cells by portal vein resection (Grade C1).
CQ4-4 Is a radical resection with extended lymph node dissection useful for pancreatic cancer?
The contribution of extended lymph node and nerve plexus dissection to the improvement of clinical course of patients with pancreatic cancer is unclear and there is no evidence to support the performance of such an extended radical resection (Grade C2). CQ4-5 Is the incidence of complications after pancreas resection low in a high volume center? RECOMMENDATION 4-5
The incidence of complications tends to be low in pancreatic surgery including pancreatoduodenectomy and the management of complications tends to be superior in institutions with a high volume of pancreatic surgery (Grade B).
CQ4-6 Is surgical bypass or biliary stent significant in unresectable pancreatic cancer? RECOMMENDATION 4-6
Hepaticojejunostomy for the obstructive jaundice and prophylactic gastrojejunostomy is recommended in patients with unresectable obstructive jaundice after laparotomy (Grade B). There is no definite international consensus on post-operative adjuvant therapy. Post-operative GEM is safe and effective and is recommended as post-operative chemotherapy (Grade B).
Adjuvant therapy
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